Seroconversions

INDICATION

DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP™ is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

Few seroconversions were observed1

DESCOVY FOR PrEP™ was noninferior to TRUVADA

  • Of the seroconversions observed, 1 patient in the DESCOVY arm and 4 patients in the TRUVADA arm had suspected baseline infections1
  • Primary analysis: when 100% of patients reached Week 48 and ≥50% reached Week 96

Adherence testing:
Dried blood spot tests were used to measure drug levels in patients during the trial.

  • Median intracellular drug levels were substantially lower in participants infected with HIV compared with uninfected matched controls
DISCOVER Trial Baseline Characteristics

Efficacy is strongly correlated with adherence.

Switch Subset